NO20061284L - Therapeutic regimes for the administration of drug combinations - Google Patents
Therapeutic regimes for the administration of drug combinationsInfo
- Publication number
- NO20061284L NO20061284L NO20061284A NO20061284A NO20061284L NO 20061284 L NO20061284 L NO 20061284L NO 20061284 A NO20061284 A NO 20061284A NO 20061284 A NO20061284 A NO 20061284A NO 20061284 L NO20061284 L NO 20061284L
- Authority
- NO
- Norway
- Prior art keywords
- administration
- drug combinations
- therapeutic regimes
- combination
- regimes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
Abstract
Oppfinnelsen angår doseringsregimer for administrering av kombinasjonsterapier, hvor ett av medikamentene i kombinasjonen er formulert for langvarig frigjøring, eller administreres gjentatte ganger, og preparater i forbindelse med disse.This invention relates to dosage regimens for the administration of combination therapies, wherein one of the drugs in the combination is formulated for sustained release, or administered repeatedly, and compositions associated therewith.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/670,488 US20040220153A1 (en) | 2002-09-24 | 2003-09-24 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
US51241503P | 2003-10-15 | 2003-10-15 | |
US52044603P | 2003-11-13 | 2003-11-13 | |
US10/777,517 US20040229849A1 (en) | 2002-09-24 | 2004-02-12 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
US10/777,518 US20040224876A1 (en) | 2003-02-14 | 2004-02-12 | Combination therapy for the treatment of immunoinflammatory disorders |
US55749604P | 2004-03-30 | 2004-03-30 | |
US10/944,574 US20050137185A1 (en) | 2003-09-18 | 2004-09-17 | Combinations of drugs for the treatment of neoplasms |
US10/947,455 US20050153947A1 (en) | 2002-09-24 | 2004-09-20 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
PCT/US2004/031195 WO2005030132A2 (en) | 2003-09-24 | 2004-09-23 | Therapeutic regimens for administering drug combinations |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20061284L true NO20061284L (en) | 2006-06-22 |
Family
ID=46123823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20061284A NO20061284L (en) | 2003-09-24 | 2006-03-21 | Therapeutic regimes for the administration of drug combinations |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1675550A4 (en) |
JP (1) | JP2007517766A (en) |
KR (1) | KR20060076319A (en) |
AU (1) | AU2004275777A1 (en) |
BR (1) | BRPI0414719A (en) |
CA (1) | CA2538023A1 (en) |
IS (1) | IS8413A (en) |
MX (1) | MXPA06003320A (en) |
NO (1) | NO20061284L (en) |
WO (1) | WO2005030132A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040224876A1 (en) * | 2003-02-14 | 2004-11-11 | Jost-Price Edward Roydon | Combination therapy for the treatment of immunoinflammatory disorders |
BRPI0414541B8 (en) | 2003-09-17 | 2021-05-25 | Janssen Pharmaceutica Nv | fused heterocyclic compounds having serotonin receptor modulating activity, method of preparing intermediate compounds |
TW200517114A (en) * | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
CN1980649A (en) * | 2004-05-17 | 2007-06-13 | 康宾纳特克斯公司 | Methods and reagents for the treatment of immunoinflammatory disorders |
US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
TW200932240A (en) * | 2007-10-25 | 2009-08-01 | Astellas Pharma Inc | Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production |
CA2822683C (en) * | 2011-01-04 | 2015-05-12 | Ista Pharmaceuticals, Inc. | Bepotastine compositions |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4618677A (en) * | 1984-05-31 | 1986-10-21 | Boehringer Ingelheim Limited | Substituted phenylalkyl-(piperazinyl or homopiperazinyl)alkyl-thiols and -thiocarbamates useful for the treatment of immunological, inflammatory, and allergic disorders |
TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
JP3962108B2 (en) * | 1995-04-03 | 2007-08-22 | 中外製薬株式会社 | Sucralfate-containing pharmaceutical composition |
WO2001045703A1 (en) * | 1999-12-23 | 2001-06-28 | Nitromed, Inc. | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
DE60233414D1 (en) * | 2001-07-09 | 2009-10-01 | Combinatorx Inc | COMBINATIONS FOR THE TREATMENT OF INFLAMMATORY DISEASES |
EP1350512A1 (en) * | 2002-04-03 | 2003-10-08 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Combinations of epinastine, belladonna and pseudoephedrine as new pharmaceutical formulations |
AU2002253425B2 (en) * | 2002-04-04 | 2008-09-25 | Dr. Reddy's Laboratories Ltd. | Novel pharmaceutical compositions for antihistaminic-decongenstant combination and method of making such compositions |
EA007156B1 (en) * | 2002-04-15 | 2006-08-25 | Адамс Лэборетриз, Инк. | Sustained release of guaifenesin combination drugs |
BR0313745A (en) * | 2002-08-23 | 2005-07-12 | Ranbaxy Lab Ltd | Nitrofurantoin controlled release pharmaceutical presentation and preparation process |
BR0314713A (en) * | 2002-09-24 | 2005-07-26 | Combinatorx Inc | Processes and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines. |
-
2004
- 2004-09-23 BR BRPI0414719-7A patent/BRPI0414719A/en not_active IP Right Cessation
- 2004-09-23 WO PCT/US2004/031195 patent/WO2005030132A2/en active Application Filing
- 2004-09-23 JP JP2006528154A patent/JP2007517766A/en active Pending
- 2004-09-23 AU AU2004275777A patent/AU2004275777A1/en not_active Abandoned
- 2004-09-23 MX MXPA06003320A patent/MXPA06003320A/en not_active Application Discontinuation
- 2004-09-23 KR KR1020067007818A patent/KR20060076319A/en not_active Application Discontinuation
- 2004-09-23 EP EP04788933A patent/EP1675550A4/en not_active Withdrawn
- 2004-09-23 CA CA002538023A patent/CA2538023A1/en not_active Abandoned
-
2006
- 2006-03-21 NO NO20061284A patent/NO20061284L/en not_active Application Discontinuation
- 2006-04-12 IS IS8413A patent/IS8413A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2538023A1 (en) | 2005-04-07 |
JP2007517766A (en) | 2007-07-05 |
IS8413A (en) | 2006-04-12 |
WO2005030132A3 (en) | 2006-10-12 |
BRPI0414719A (en) | 2006-11-21 |
WO2005030132A2 (en) | 2005-04-07 |
AU2004275777A1 (en) | 2005-04-07 |
KR20060076319A (en) | 2006-07-04 |
EP1675550A2 (en) | 2006-07-05 |
EP1675550A4 (en) | 2007-10-10 |
MXPA06003320A (en) | 2006-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062504L (en) | Compositions and dosage forms for improved absorption | |
NO20061284L (en) | Therapeutic regimes for the administration of drug combinations | |
ES2653615T3 (en) | Plurality of recombinant LAG-3 dose for use in eliciting an immune response from monocytes | |
ATE478658T1 (en) | SOLID MEDICINAL FORM FOR ORAL ADMINISTRATION DESIGNED TO PREVENT ABUSE | |
LTPA2017009I1 (en) | Bruton tyrosine kinase inhibitors | |
RU2007132181A (en) | ANTI-CANCER MEDICINE CONTAINING α, α, α-TRIFTORTIMIDINE AND A THIMIDINFOSPHORILYLASE INHIBITOR | |
AR049985A1 (en) | COMBINATION TREATMENT FOR NON-HEMATOLOGICAL MALIGNAL DISEASES | |
EA200501203A1 (en) | LIQUID PHARMACEUTICAL COMPOSITIONS OF PALONOSETRON | |
NO20064584L (en) | Tetrahydropyridoindolderivater | |
EA200700362A1 (en) | CONJUGAT, CONTAINING ANTI-VIRUS COMPOUND, IN PARTICULAR INHIBITING HIV, PHARMACEUTICAL COMPOSITION AND SET OF STANDARD DOSE OF THE MEDICINAL DRUG ON ITS BASIS, METHOD OF INHIBITING THE SOFTWARE PRO. | |
NO20051941L (en) | Combination chemotherapy compositions and methods. | |
MY141025A (en) | Dose forms | |
NO20072931L (en) | Improved dosing regimen of temozolomide for the treatment of cancer based on the patient's MGMT level | |
NO20073059L (en) | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | |
SG148169A1 (en) | Combination drug therapy to treat obesity | |
TW200501945A (en) | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | |
EP1503748A4 (en) | Drugs for mitigating taxane-induced neurotoxicity | |
NO20091628L (en) | combination Drug | |
ATE413187T1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING INTERFERON TAU | |
BRPI0510855A (en) | medicament in film form for oral administration and use of pharmaceutically acceptable estriol and / or estriol esters | |
MA31227B1 (en) | PHARMACEUTICAL COMPOSITION COMPRISING PHLOROGLUCINOL AND PARACETAMOL. | |
WO2004033484A3 (en) | Use of stable glutamine derivatives to improve drug absorption | |
NO20075508L (en) | Stable Soporphine Preparations and Administration | |
SE0203817D0 (en) | New composition | |
SG146671A1 (en) | Therapeutic regimens for administering drug combinations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |